Start Date
February 1, 2025
Primary Completion Date
November 16, 2025
Study Completion Date
May 17, 2026
coformulated CIC Vaccine
SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)
Fluzone HD trivalent
60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
Lead Sponsor
Novavax
INDUSTRY